Biofrontera (NASDAQ:BFRI) Announces Quarterly Earnings Results

Biofrontera (NASDAQ:BFRI) posted its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%.

Here are the key takeaways from Biofrontera’s conference call:

• Q2 revenue rose 33% to $12.0 million, driven by approximately 30% Ameluz unit-volume growth and the 2025 price increase. Gross margin expanded to about 80%, while adjusted EBITDA improved to near breakeven from a $5.1 million loss a year earlier.
• Commercial momentum continued, with first-half order count up 18.6%, average tubes per order up 10%, and the installed base reaching approximately 801 lamps across 740 physician offices. Management said more than 81% of customers that made large pre-price-increase purchases reordered in the first half.
• The ITC exclusion order bars Biofrontera from importing or selling the current RhodoLED XL lamp and restricts Ameluz sales for use with that device. The company is pursuing an appeal and a minor lamp redesign, but must still obtain clearance from border authorities; approximately 243 XL lamps are affected.
• Biofrontera expects potential FDA approval for superficial basal cell carcinoma on September 28, 2026, with a planned first-quarter 2027 launch using its existing lamps and sales force. It also plans to file an expanded actinic keratosis indication by the end of the third quarter and is advancing an acne program toward Phase III.
• Liquidity remains a constraint, with $4.7 million in cash at June 30 and a going-concern qualification in the financial statements. Management expects to reach cash-flow breakeven in 2026 but may need a working-capital facility, while future clinical development depends on available funding.

Biofrontera Stock Up 6.0%

Shares of BFRI stock traded up $0.07 during trading hours on Thursday, hitting $1.32. 888,010 shares of the company were exchanged, compared to its average volume of 355,821. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20. Biofrontera has a one year low of $0.55 and a one year high of $1.40. The business’s 50-day simple moving average is $1.07 and its two-hundred day simple moving average is $0.98. The stock has a market capitalization of $16.96 million, a price-to-earnings ratio of -1.37 and a beta of 0.78.

Institutional Trading of Biofrontera

An institutional investor recently raised its stake in Biofrontera stock. Geode Capital Management LLC grew its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,677 shares of the company’s stock after buying an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. Institutional investors own 10.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on BFRI shares. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. Finally, Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.